Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
8.05
-0.04 (-0.49%)
After Hours: 8.05 0.00 (0.00%)
Jun 30, 4:37PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.96 - 8.17
52 week 7.90 - 21.65
Open 8.15
Vol / Avg. 98,272.00/161,917.00
Mkt cap 204.47M
P/E     -
Div/yield     -
EPS -1.81
Shares 24.77M
Beta 1.76
Inst. own 89%
Aug 8, 2016
Q2 2016 Zogenix Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 7, 2016
Zogenix Inc at Jefferies Healthcare Conference
May 10, 2016
Q1 2016 Zogenix Inc Earnings Call - Webcast
May 10, 2016
Q1 2016 Zogenix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -111.01% -153.43%
Operating margin -152.94% -175.58%
EBITD margin - -169.62%
Return on average assets -13.84% -16.40%
Return on average equity -22.99% -35.04%
Employees 62 -
CDP Score - -

Address

5858 Horton St Ste 455
EMERYVILLE, CA 94608-2072
United States - Map
+1-510-5508300 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company's areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 53
Bio & Compensation  - Reuters
Gail M. Farfel Ph.D. Executive Vice President, Chief Development Officer
Age: 51
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Thierry J P Darcis Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Roger L. Hawley Director
Age: 62
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 52
Bio & Compensation  - Reuters
Mark C. Wiggins Independent Director
Age: 59
Bio & Compensation  - Reuters